Home MarketStrides Shasun Ltd.

Strides Shasun Ltd. Stock Info: As on 2017-05-26 15:57:16

Nse

916.20

18.90(2.11%)
Change%
52 Week Range
848.00
24.00
1,274.70
3.00
Open904.80
Day's Range807.57 - 987.03
Value Traded (in ₹ Cr.) 26.27

Bse

918.00

20.35(2.27%)
Change %
52 Week Range
848.50
24.00
1,259.00
3.00
Open900.00
Day's Range807.89 - 987.42
Value Traded (in ₹ Cr.) 4.42

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 27,798,384.00 31.09%
Mutual Funds/UTI 11,209,440.00 12.54%
FII 30,845,238.00 34.49%
Employee 0.00 0.00%
Public 11,902,841.00 13.31%
Government 0.00 0.00%
Others 5,999,622.00 6.71%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.41
Basic EPS (Rs.) 19.50
Cash EPS 29.87
BVPerShare Excl 350.93
Operating Revenue 246.62
PBDITPerShare 47.35
Dividend 4.00
NPPerShare 18.03
Current Ratio 2.06
Quick Ratio 1.77
PriceToBV 3.10
Earnings 0.01
PBDIT Margin 19.19
PBT Margin 8.59
NP Margin 7.30
Return On Assets 3.00
Retention Ratios 73.63
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,344.45
Total Expenses 2,129.99
EBITDA 423.02
PBT 189.29
PAT 161.07
Net Income 161.07
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,244.33
Total Expenses 1,082.98
EBITDA 106.21
PBT 108.08
PAT 108.97
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 89.35
Net worth 3,135.41
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 89.35
Net worth 3,135.40
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

501.5 482.4 3.96
447.8538.9

Abbott India Ltd.

4114.25 4102 0.3
40754235.9

Ajanta Pharma Ltd.

1602.15 1616.15 -0.87
1569.151696.95

Albert David Ltd.

292.85 298.65 -1.94
283329.75

Alembic Ltd.

42.5 42.35 0.35
40.445.3

Alembic Pharmaceuticals Ltd.

558.15 570.4 -2.15
548610

Alkem Laboratories Ltd.

1872.4 1836.95 1.93
18091931
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

115.85 116 -0.13
112.5119.3

Aarti Drugs Ltd.

498.95 486.55 2.55
456.25539

Aayush Food & Herbs Ltd.

48.55 48.55 0
48.5548.55

Abbott India Ltd.

4103.5 4101.35 0.05
40504238

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 83.56
Cash from investing activities -1,064.38
Cash from financing activities 1,570.84
Net change in cash 591.96

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
SBI Blue Chip Fund 1.75%
SBI Magnum Midcap Fund 4.11%
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.72%
SBI Pharma Fund 9.53%
Tata Balanced Fund - Regular Plan 0.91%
Sundaram Select Midcap 1.04%

Tech Mah Q4 net falls 30.2% qoq to Rs 589.69 cr

IT services firm Tech Mahindra Ltd on Friday reported a drop of 30.2 per cent in its consolidated net profit after tax at Rs 589.69 crore sequentially for the March quarter of FY17, as compared to Rs 844.86 crore in December quarter. “The consolidated net profit of the IT major stood at Rs 876.14 crore during the same quarter a year ago,” Tech Mahindra Ltd said in a filing to the Bombay Stock Exchange on May 26, 2017. The consolidated total income of Tech Mahindra witnessed a marginal increase of 0.3 per cent to Rs 7,732.89 crore sequentially in Q4 FY17, against Rs 7,712.68 crore in previous quarter. Further, on y-o-y basis, its total income grew by 9.9 per cent from Rs 7,039.03 crore in Q4 FY16. Commenting on the performance, Tech Mahindra Ltd, Vice Chairman, Vineet Nayyar said, “Information technology, the world over is going through a major shift with demand patterns changing constantly. Most businesses are also battling the geopolitical uncertainties and as a digital transformation company, we see these as huge opportunities in the future.” In dollar terms, its net profit down 29.3 per cent q-o-q while 30 per cent y-o-y at USD 89.1 million during the quarter under review. On the other hand, its revenue grew by 1.3 per cent qoq and 10.6 per cent y-o-y at USD 1,131.2 million in Q4 FY 17. The company’s board has recommended a dividend of Rs 9 per share on par value of Rs 5 (180 per cent) for the financial year ended March 31, 2017, subject to approval by the members of the company at the forthcoming AGM. Meanwhile, shares of the company closed at Rs 429.35 apiece, up 0.61 per cent, from previous close on BSE.

26-05-2017 18:20

Tata Chemicals Q4 net profit up 32% at Rs 343 cr

Tata Chemicals today reported a 31.82 per cent increase in consolidated net profit at Rs 343.02 crore in the fourth quarter of 2016-17 fiscal even as income remained down. Its net profit stood at Rs 260.21 crore in the year-ago period, the company said in a BSE filing. Total income declined to Rs 3,079.47 crore in the January-March quarter of the 2016-17 fiscal from Rs 3,618.14 crore in the year-ago period. However, expenses remained lower at Rs 2,733.96 crore as compared to Rs 3,310.56 crore in the said period. For the FY 2016-17, net profit rose to Rs 1,234.10 crore from Rs 1,001.11 crore in the previous fiscal. The board has recommended a dividend of Rs 11 per ordinary share of Rs 10 each for the 2016-17 fiscal, subject to the approval of the shareholders at the ensuing annual general meeting of the company. The dividend, if approved, will be paid on and from August 11, 2017. Tata Chemicals, a Tata group company, is engaged in manufacturing of chemicals, salt and fertilisers. It also sells pulses and spices under Tata Sampann brand. The firm is also into water purifier business. Meanwhile, shares of the company closed trading at Rs 612.10 apiece, down 0.46 per cent from the previous close on BSE.

26-05-2017 16:53

Gujarat State Petronet Q4 net rises 27.7% to Rs 126.98 cr

Gujarat State Petronet Ltd (GSPL) has reported a surge of 27.7 per cent in its standalone net profit after taxes (PAT) at Rs 126.98 crore for the fourth quarter ended March 31, 2017. “The standalone PAT of the company stood at Rs 99.45 crore during the same period a year ago,” said Gujarat State Petronet Ltd in a filing to the Bombay Stock Exchange. Further, the standalone total income of the company grew by 10.8 per cent to Rs 271.94 crore during Q4 2016-17, as compared to Rs 245.39 crore during the same period last year. The company’s board has recommended a dividend of Rs 1.50 per share of Rs 10 each (i.e. at the rate of 15 per cent) for the FY 2016-17. Meanwhile, shares of the company closed at Rs 170.30 apiece, down 1.99 per cent, from previous close on BSE.

26-05-2017 16:04

HPCL Q4 net surges 31% at Rs 1,819 cr

State-run Hindustan Petroleum Corporation Ltd (HPCL) on Friday reported a 31.04 per cent growth in its standalone net profit at Rs 1,818.79 crore for the fourth quarter ended March 31, 2017. “The company had posted standalone net profit of Rs 1,387.91 crore in the year ago period,” said HPCL in a filing to Bombay Stock Exchange. The standalone total revenue of the company rose by 21.71 per cent to Rs 59,183.49 crore in Q4 FY17 compared to Rs 48,625.27 crore in Q4 FY16. During the quarter under review, domestic sales was flat at 8.76 million metric tonnes while export sales doubled to 0.1 million metric tonnes compared to the previous quarter. For FY 2016-17, the company has posted net profit of Rs 6,208.80 crore against total revenue of Rs 215,317.71 crore. The company in a separate release said that its board has recommended a final dividend of Rs 1.10 per share of Rs 10 each for the Financial Year 2016-2017 subject to the approval of the shareholders at the ensuring Annual General Meeting. The final dividend shall be paid within 30 days from the date of its declaration at the AGM. Meanwhile, shares of company closed day’s trade at Rs 567.45 apiece, up 11.43 per cent, on the BSE.

26-05-2017 16:04

ITC Q4 net rises 12% at Rs 2,669 cr

ITC, India’s leading fast-moving consumer goods company, on Friday reported a 12.13 per cent growth in its standalone net profit at Rs 2,669.47 crore for the fourth quarter ended March 31, 2017, helped by spurt in revenue from cigarette segment. “The company had posted standalone net profit of Rs 2,380.68 crore in the year ago period,” said ITC in a filing to Bombay Stock Exchange. The standalone total revenue of the company rose by 4.8 per cent to Rs 15,008.82 crore in Q4 FY17 compared to Rs 14,138.78 crore in Q4 FY16. During the quarter under review, cigarette and other FMCG products posted revenue of Rs 11,840.70 crore, compared with Rs 11,256.24 crore-revenue in the year-ago quarter. Among others, businesses such as hotels, agri business, paperboards and packaging increased to Rs 15,518.44 crore from Rs 14,741.05 crore in the year ago period. The company in a separate release said that its board has recommended dividend of Rs 4.75 per ordinary share of Rs 1 each for the financial year ended 31st March, 2017, subject to declaration of the same by the Members at the 106th Annual General Meeting of the Company convened for Friday, 28th July, 2017. The dividend, if declared, will be paid on Monday, 31st July, 2017 to those Members entitled thereto. Boosted by the strong Q4, shares of company were trading 0.94 per cent higher at Rs 653.00 apiece on the BSE at 15:05 hours.

26-05-2017 15:49

Strides Shasun L - Updates

Declaration on Unmodified Opinion in the Auditors' Report for Financial Year 2016-17

26-May-2017 01:04 PM

Strides Shasun bags approval for Memantine Tablets

Leading pharma company, Strides Shasun has said that it has received approval from the USFDA for Memantine Hydrochloride Tablets USP, 5 mg and 10 mg. “The product will be manufactured at the Company's flagship facility at Bangalore and marketed by Strides Pharma Inc in the US market. The product will be launched immediately,” the company said in a filing to the Bombay Stock Exchange. Headquartered in India, Strides Arcolab is a pharmaceutical company with a key focus on development and manufacture of IP-led niche generics and bio-pharmaceuticals. Shasun Pharmaceuticals Limited has merged with Strides Arcolab Limited w.e.f November 19, 2015, consequent to receipt of all statutory/ regulatory approvals for the Merger. Further, the name of Strides Arcolab Limited has also changed to ‘STRIDES SHASUN LIMITED’. Meanwhile, shares of the company were trading at Rs 900.55 apiece, up 0.66 per cent from the previous close at 11:50 hours on BSE.

24-May-2017 11:44 AM

Strides Shasun L - Press Release

Strides Shasun receives USFDA Approval for Memantine Hydrochloride Tablets

24-May-2017 10:52 AM

Strides Shasun inks JV pact with Vivimed Labs

Drug firm Strides Shasun said that it has inked a pact with Vivimed Labs to set up two joint venture firms. The first JV -- a 50:50 joint venture company in India will own a USFDA approved formulation facility in Alathur, Chennai, Strides Shasun said in a regulatory filing. The second JV firm would come up in Singapore and will own various approved abbreviated new drug applications (ANDAs) and product pipeline, it added. The exercise provides additional capacity and derisks manufacturing infrastructure, the company said. The transaction is expected to close on May 31, 2017.

19-May-2017 10:14 AM

Strides Shasun L - Change in Directorate

Board Reconstitution

18-May-2017 06:32 PM

Strides Shasun L - Updates

Declaration on Unmodified Opinion in the Auditors' Report for Financial Year 2016-17

26-May-2017 01:04 PM

Strides Shasun L - Press Release

Strides Shasun receives USFDA Approval for Memantine Hydrochloride Tablets

24-May-2017 10:52 AM

Strides Shasun L - Change in Directorate

Board Reconstitution

18-May-2017 06:32 PM

Corporate Details

About Management

2002 -Board approves for the allotment of 210,955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd. -Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route. -Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act. -Incorporates 'Strides Africa Ltd' at British Virgin Island with an authorised capital of US $ 200,000 as 100% wholly owned subsidiary. -Board decides to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations. 2003 -Nominates Mr Francis Pinto as the Director on the Board of the company. -Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems. -Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical products. -Changes in the Management: Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr Krishna Kumar Menon as COO. -Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company. -Strides inks MoU with Ribbon SRL for Cephalosporin 2004 -Major Fire occurs in Private Custom Bonded warehouse in Mexico -Strides Arcolab Limited has entered into a memorandum of understanding with BITS, Pilani for an ``off campus collaborative programme''. As part of the partnership, Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job. 2005 - Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets. -Strides Arcolab enters into an agreement for private placement issue - Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs -Strides acquires sterile manufacturing facility in Poland 2007 - Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets, an anti-HIV drug. Efavirenz, is the generic version of Bristol Myers Squibb's Sustiva, which helps in preventing the HIV virus from reproduction. - Strides Arcolab receives 2 more NDA approvals from US-FDA. 2008 - Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials. 2010 - Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been appointed as an Executive Director of the Company. 2011 -Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite -Strides announces First European Approval for Oncology Product -Strides Arcolab receives US FDA Nod to Commercialize First Liquid -StridesArcoL Update on acquisition of outstanding minority shareholding in Ascent Pharmahealth Limited -Strides Arcolab joins the Malaysian Bio-xcell Ecosystem 2012 -Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile -Strides Arcolab receives US FDA approval for Methotrexate Injection -Strides Arcolab Announces Health Canada Approval For Tobramycin Injection -Strides Arcolab acquires Sterile Formulations facility to expand core injectable biz -Strides collaborates with Gilead Sciences 2013 -Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet. - Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. - Strides announces WHO pre-qualification for Artemether + Lumifantrine . -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology. -Strides Arcolab - Re-branding Biotech Business as ''Stelis''. -Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market. 2014 -- Medicines for Malaria Venture announces collaborations with Cipla and Strides. -Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. - Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. -Strides Arcolab receives US FDA approval for Buspirone Tablets. -Strides Arcolab receives US FDA approval for Calcitriol Softgel. -Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. -Strides Arcolab to acquire Shasun Pharma in all stock deal. 2015 -Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc -Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc, -Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India "Virso" -Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug -Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company. -Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia. -Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy -Strides Arcolab Ltd has changed from its present name "Strides Arcolab Limited" to "Strides Shasun Limited" 2016 -Strides Shasun updates on "Acquisition of seven brands from Johnson & Johnson". -Strides Shasun update on "Acquisition of CNS divisions of erstwhile Ranbaxy". -"Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia". -"Strides Shasun to acquire controlling stake in Universal Corporation, Kenya". -"Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet". - "Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore".

Registered Office

201, Devavrata, Sector 17, Vashi

022-27895247,27893199,,      022-27892924,

info@stridesshasun.com

http://www.stridesarco.com

Registrar Details

Karvy Computershare Private Ltd.